|
Quanterix Corporation (NASDAQ: QTRX) |
|
|
|
|
Select the Financial Report:
|
|
Select the Period:
|
|
Description of Quanterix's Business Segments
Quanterix Corp is well-established as a prominent player in the healthcare technology domain, committed to delivering ultra-sensitive diagnostic tests capable of identifying diseases at their nascent stages. The organizations mission centers on transforming precision medicine through the development and provision of life sciences tools and solutions that facilitate disease investigation, ultimately contributing to enhanced understanding, diagnosis, and treatment of patients. Quanterixs offerings span various segments, products, and services carefully curated to cater to the diverse needs of its clientele.
Segments
1. Life Sciences Research:
In the life sciences research segment, Quanterix delivers a variety of reagents, assays, and imaging consumables along with its flagship immunoassay platform known as Simoa (Single Molecule Array). This platform distinguishes itself by its ability to detect and quantify proteins and other molecules at exceedingly low concentrations, which is crucial for researchers aiming to delve deep into disease mechanisms and pathways. This segment supports a broad spectrum of research including drug discovery and development, biomarker validation, and clinical trial sample analysis.
2. In Vitro Diagnostics (IVD):
Quanterix is at the vanguard of the in vitro diagnostics segment, focusing on the development, manufacture, and distribution of ultra-sensitive diagnostic tests that can potentially detect diseases long before conventional methods. The IVD offerings incorporate a variety of Simoa-based tests catering to multiple medical fields, such as:
- Cardiology: Tests aimed at heart diseases, measuring biomarkers related to cardiac health.
- Neurology: Diagnostic assays that focus on neurodegenerative diseases such as Alzheimer's and Multiple Sclerosis.
- Oncology: Tests that are designed for the detection of cancer-associated biomarkers, thereby aiding in early diagnosis and treatment decisions.
- Infectious Diseases: Simoa assays that assist in the detection and quantification of pathogens or markers associated with infectious diseases.
Products
1. Simoa HD-X Analyzer:
This state-of-the-art analyzer is pivotal in Quanterixs offering. The HD-X Analyzer is noted for its unparalleled sensitivity, allowing for the detection and quantification of proteins and other molecules at extremely low concentrations. Its high throughput and reproducibility make it a vital tool for both research and clinical laboratories in the quest to uncover disease insights.
2. Simoa Assays:
Quanterix offers a comprehensive suite of Simoa assays tailored to different applications. These assays utilize the HD-X Analyzers capabilities and span various medical domains such as cardiology, oncology, infectious diseases, and neurology. Each assay is designed to facilitate the detection of biomarkers that are critical for understanding disease progression and treatment efficacy.
3. Quanterix Homebrew Kits:
These kits empower researchers with the autonomy to develop custom assays tailored to their unique research needs. Utilizing the Simoa technology, the homebrew kits provide the flexibility necessary for research teams to innovate and explore specific biomarkers of interest.
Services
1. Assay Development Services:
Quanterix offers expert guidance and support in assay development through services that allow collaboration with their knowledgeable scientists. This personalized service aids researchers in developing and optimizing custom assays capable of detecting particular biomarkers pertinent to their studies.
2. Contract Research Services:
Through its contract research offerings, Quanterix supports clients in various research endeavors. The services encompass a broad spectrum, including assay development, sample analysis, and comprehensive data analysis, facilitating a full research cycle from development to actionable insights.
3. Technical Support Services:
Understanding that effective utilization of their products and services is crucial, Quanterix provides extensive technical support to address queries and concerns that customers may have. This ensures that clients can maximize the potential of their Quanterix solutions and streamline their research and diagnostic processes.
Conclusion
Overall, Quanterix Corp presents an extensive range of life science tools, innovative technologies, potent products, and supportive services. This comprehensive portfolio is strategically designed to empower researchers, clinicians, and diagnostic laboratories to deepen their understanding of various diseases, develop novel therapeutic approaches, and enhance disease diagnosis through the pioneering Simoa technology. Quanterix's commitment to advancing healthcare through precision medicine continues to make a significant impact in both research and clinical settings.
Composition of Quanterix Corporation Revenues by
Segments |
| |
| Product revenue |
|
 70.5 % |
of total Revenue |
| Product revenue North America |
|
39.88 % |
of total Revenue |
| Product revenue EMEA |
|
17.72 % |
of total Revenue |
| Product revenue Asia Pacific |
|
12.91 % |
of total Revenue |
| Instruments |
|
8.92 % |
of total Revenue |
| Instruments North America |
|
2.76 % |
of total Revenue |
| Instruments EMEA |
|
1.23 % |
of total Revenue |
| Instruments Asia Pacific |
|
4.92 % |
of total Revenue |
| Consumable and other products |
|
61.59 % |
of total Revenue |
| Consumable and other products North America |
|
37.12 % |
of total Revenue |
| Consumable and other products EMEA |
|
16.48 % |
of total Revenue |
| Consumable and other products Asia Pacific |
|
7.99 % |
of total Revenue |
| Service and other revenue |
|
29.79 % |
of total Revenue |
| Service and other revenue North America |
|
23.38 % |
of total Revenue |
| Service and other revenue EMEA |
|
4.84 % |
of total Revenue |
| Service and other revenue Asia Pacific |
|
1.57 % |
of total Revenue |
| Research services |
|
19.04 % |
of total Revenue |
| Research services North America |
|
17.02 % |
of total Revenue |
| Research services EMEA |
|
1.12 % |
of total Revenue |
| Research services Asia Pacific |
|
0.9 % |
of total Revenue |
| Service-type warranties |
|
8.82 % |
of total Revenue |
| Service-type warranties North America |
|
5.13 % |
of total Revenue |
| Service-type warranties EMEA |
|
3.04 % |
of total Revenue |
| Service-type warranties Asia Pacific |
|
0.65 % |
of total Revenue |
| Other services |
|
1.93 % |
of total Revenue |
| Other services North America |
|
1.23 % |
of total Revenue |
| Other services EMEA |
|
0.69 % |
of total Revenue |
| Other services Asia Pacific |
|
0.01 % |
of total Revenue |
| Collaboration and license revenue |
|
2.62 % |
of total Revenue |
| Collaboration and license revenue North America |
|
2.62 % |
of total Revenue |
| Grant revenue |
|
0.2 % |
of total Revenue |
| Reportable Segment |
|
102.92 % |
of total Revenue |
| Reportable Grant revenue |
|
0.2 % |
of total Revenue |
Q1 three months ended (Mar 31 2025)
|
| Revenues by Business Segments |
Revenues
(in millions $) |
%
(of total Revenues) |
| Product revenue |
20.74 |
70.5 % |
| Product revenue North America |
11.73 |
39.88 % |
| Product revenue EMEA |
5.21 |
17.72 % |
| Product revenue Asia Pacific |
3.80 |
12.91 % |
| Instruments |
2.62 |
8.92 % |
| Instruments North America |
0.81 |
2.76 % |
| Instruments EMEA |
0.36 |
1.23 % |
| Instruments Asia Pacific |
1.45 |
4.92 % |
| Consumable and other products |
18.12 |
61.59 % |
| Consumable and other products North America |
10.92 |
37.12 % |
| Consumable and other products EMEA |
4.85 |
16.48 % |
| Consumable and other products Asia Pacific |
2.35 |
7.99 % |
| Service and other revenue |
8.76 |
29.79 % |
| Service and other revenue North America |
6.88 |
23.38 % |
| Service and other revenue EMEA |
1.42 |
4.84 % |
| Service and other revenue Asia Pacific |
0.46 |
1.57 % |
| Research services |
5.60 |
19.04 % |
| Research services North America |
5.01 |
17.02 % |
| Research services EMEA |
0.33 |
1.12 % |
| Research services Asia Pacific |
0.27 |
0.9 % |
| Service-type warranties |
2.59 |
8.82 % |
| Service-type warranties North America |
1.51 |
5.13 % |
| Service-type warranties EMEA |
0.89 |
3.04 % |
| Service-type warranties Asia Pacific |
0.19 |
0.65 % |
| Other services |
0.57 |
1.93 % |
| Other services North America |
0.36 |
1.23 % |
| Other services EMEA |
0.20 |
0.69 % |
| Other services Asia Pacific |
0.00 |
0.01 % |
| Collaboration and license revenue |
0.77 |
2.62 % |
| Collaboration and license revenue North America |
0.77 |
2.62 % |
| Grant revenue |
0.06 |
0.2 % |
| Reportable Segment |
30.27 |
102.92 % |
| Reportable Grant revenue |
0.06 |
0.2 % |
| Total |
29.42 |
100 % |
Q1 three months ended (Mar 31 2025)
|
| Revenue Growth rates by Segment |
Y/Y Revenue
% |
Q/Q Revenue
% |
| Product revenue |
5.43 % |
- |
| Product revenue North America |
9.58 % |
- |
| Product revenue EMEA |
-6.41 % |
- |
| Product revenue Asia Pacific |
11.78 % |
- |
| Instruments |
3.02 % |
- |
| Instruments North America |
99.26 % |
- |
| Instruments EMEA |
-71.47 % |
- |
| Instruments Asia Pacific |
66.63 % |
- |
| Consumable and other products |
5.79 % |
- |
| Consumable and other products North America |
6.03 % |
- |
| Consumable and other products EMEA |
12.79 % |
- |
| Consumable and other products Asia Pacific |
-7.08 % |
- |
| Service and other revenue |
-26.77 % |
- |
| Service and other revenue North America |
-10.89 % |
- |
| Service and other revenue EMEA |
-63.51 % |
- |
| Service and other revenue Asia Pacific |
32.76 % |
- |
| Research services |
-35.55 % |
- |
| Research services North America |
-13.12 % |
- |
| Research services EMEA |
-88.26 % |
- |
| Research services Asia Pacific |
109.45 % |
- |
| Service-type warranties |
-3.32 % |
- |
| Service-type warranties North America |
-7.82 % |
- |
| Service-type warranties EMEA |
4.81 % |
- |
| Service-type warranties Asia Pacific |
-1.03 % |
- |
| Other services |
-4.22 % |
- |
| Other services North America |
13.84 % |
- |
| Other services EMEA |
-18.55 % |
- |
| Other services Asia Pacific |
-85.19 % |
- |
| Collaboration and license revenue |
397.42 % |
- |
| Collaboration and license revenue North America |
397.42 % |
- |
| Grant revenue |
-78.1 % |
- |
| Reportable Segment |
-4.78 % |
- |
| Reportable Grant revenue |
-78.1 % |
- |
| Total |
-6.76 % |
-78.55 % |
Q1 three months ended (Mar 31 2025)
|
| Income by Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
-20.50 |
- |
Q1 three months ended (Mar 31 2025)
|
| Income Growth rates by Segment |
Y/Y Income
% |
Q/Q Income
% |
| Total |
- |
- |
Annual Report on Quanterix Corporation Divisions, Sales by Country |
| |
| Product revenue |
|
58.16 % |
of total Revenue |
| Product revenue North America |
|
31.89 % |
of total Revenue |
| Product revenue EMEA |
|
17.95 % |
of total Revenue |
| Product revenue Asia Pacific |
|
8.32 % |
of total Revenue |
| Instruments |
|
7.64 % |
of total Revenue |
| Instruments North America |
|
2.86 % |
of total Revenue |
| Instruments EMEA |
|
2.81 % |
of total Revenue |
| Instruments Asia Pacific |
|
1.97 % |
of total Revenue |
| Consumable and other products |
|
50.52 % |
of total Revenue |
| Consumable and other products North America |
|
29.02 % |
of total Revenue |
| Consumable and other products EMEA |
|
15.14 % |
of total Revenue |
| Consumable and other products Asia Pacific |
|
6.35 % |
of total Revenue |
| Research services |
|
27.71 % |
of total Revenue |
| Research services North America |
|
22.79 % |
of total Revenue |
| Research services EMEA |
|
4.25 % |
of total Revenue |
| Research services Asia Pacific |
|
0.67 % |
of total Revenue |
| Service-type warranties |
|
7.74 % |
of total Revenue |
| Service-type warranties North America |
|
4.61 % |
of total Revenue |
| Service-type warranties EMEA |
|
2.55 % |
of total Revenue |
| Service-type warranties Asia Pacific |
|
0.58 % |
of total Revenue |
| Other services |
|
1.92 % |
of total Revenue |
| Other services North America |
|
1.18 % |
of total Revenue |
| Other services EMEA |
|
0.71 % |
of total Revenue |
| Other services Asia Pacific |
|
0.03 % |
of total Revenue |
| Collaboration and license revenue |
|
3.25 % |
of total Revenue |
| Collaboration and license revenue North America |
|
2.68 % |
of total Revenue |
| Grant revenue |
|
1.45 % |
of total Revenue |
| Reportable Segment |
|
98.78 % |
of total Revenue |
| Alzheimer s Disease Diagnostic Fund |
|
0.8 % |
of total Revenue |
| Eli Lilly Collaboration Agreement |
|
3.28 % |
of total Revenue |
| UltraDx Limited Company |
|
0.8 % |
of total Revenue |
| Service and Other Revenue |
|
37.38 % |
of total Revenue |
| Service and Other Revenue North America |
|
28.58 % |
of total Revenue |
| Service and Other Revenue EMEA |
|
7.51 % |
of total Revenue |
| Service and Other Revenue Asia Pacific |
|
1.28 % |
of total Revenue |
| Collaboration and license revenue Asia Pacific |
|
0.56 % |
of total Revenue |
| Grant revenue National Institutes of Health |
|
0.58 % |
of total Revenue |
| Grant revenue Reportable Segment |
|
1.45 % |
of total Revenue |
Twelve months ended 2024
|
| QTRX s Annual Revenue by Geography and Business Segments |
Sales
(in millions $) |
%
(of total Sales) |
| Product revenue |
79.74 |
58.16 % |
| Product revenue North America |
43.72 |
31.89 % |
| Product revenue EMEA |
24.62 |
17.95 % |
| Product revenue Asia Pacific |
11.41 |
8.32 % |
| Instruments |
10.48 |
7.64 % |
| Instruments North America |
3.92 |
2.86 % |
| Instruments EMEA |
3.86 |
2.81 % |
| Instruments Asia Pacific |
2.70 |
1.97 % |
| Consumable and other products |
69.26 |
50.52 % |
| Consumable and other products North America |
39.79 |
29.02 % |
| Consumable and other products EMEA |
20.76 |
15.14 % |
| Consumable and other products Asia Pacific |
8.71 |
6.35 % |
| Research services |
38.00 |
27.71 % |
| Research services North America |
31.25 |
22.79 % |
| Research services EMEA |
5.83 |
4.25 % |
| Research services Asia Pacific |
0.91 |
0.67 % |
| Service-type warranties |
10.61 |
7.74 % |
| Service-type warranties North America |
6.32 |
4.61 % |
| Service-type warranties EMEA |
3.49 |
2.55 % |
| Service-type warranties Asia Pacific |
0.80 |
0.58 % |
| Other services |
2.64 |
1.92 % |
| Other services North America |
1.62 |
1.18 % |
| Other services EMEA |
0.98 |
0.71 % |
| Other services Asia Pacific |
0.05 |
0.03 % |
| Collaboration and license revenue |
4.45 |
3.25 % |
| Collaboration and license revenue North America |
3.68 |
2.68 % |
| Grant revenue |
1.99 |
1.45 % |
| Reportable Segment |
135.44 |
98.78 % |
| Total |
137.10 |
100 % |
| Alzheimer s Disease Diagnostic Fund |
1.10 |
0.8 % |
| Eli Lilly Collaboration Agreement |
4.50 |
3.28 % |
| UltraDx Limited Company |
1.10 |
0.8 % |
| Service and Other Revenue |
51.24 |
37.38 % |
| Service and Other Revenue North America |
39.19 |
28.58 % |
| Service and Other Revenue EMEA |
10.30 |
7.51 % |
| Service and Other Revenue Asia Pacific |
1.76 |
1.28 % |
| Collaboration and license revenue Asia Pacific |
0.77 |
0.56 % |
| Grant revenue National Institutes of Health |
0.80 |
0.58 % |
| Grant revenue Reportable Segment |
1.99 |
1.45 % |
Twelve months ended 2024
|
| QTRX s Annual Income by Country and Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
-38.53 |
- |
Twelve months ended 2024
|
| Annual Revenue and Income Growth by Country and Business Segments |
% Y/Y Sales Growth |
% Y/Y Income Growth |
| Product revenue |
0.09 % |
- |
| Product revenue North America |
5.35 % |
- |
| Product revenue EMEA |
-3.84 % |
- |
| Product revenue Asia Pacific |
-9.3 % |
- |
| Instruments |
-33.27 % |
- |
| Instruments North America |
-38.44 % |
- |
| Instruments EMEA |
-12.02 % |
- |
| Instruments Asia Pacific |
-45.44 % |
- |
| Consumable and other products |
8.28 % |
- |
| Consumable and other products North America |
13.3 % |
- |
| Consumable and other products EMEA |
-2.15 % |
- |
| Consumable and other products Asia Pacific |
14.15 % |
- |
| Service and other revenue |
- |
- |
| Research services |
36.55 % |
- |
| Research services North America |
26.5 % |
- |
| Research services EMEA |
191.65 % |
- |
| Research services Asia Pacific |
-18.63 % |
- |
| Service-type warranties |
7.37 % |
- |
| Service-type warranties North America |
0.86 % |
- |
| Service-type warranties EMEA |
16.29 % |
- |
| Service-type warranties Asia Pacific |
30.18 % |
- |
| Other services |
10.79 % |
- |
| Other services North America |
12.67 % |
- |
| Other services EMEA |
2.63 % |
- |
| Other services Asia Pacific |
- |
- |
| Collaboration and license revenue |
222.61 % |
- |
| Collaboration and license revenue North America |
166.74 % |
- |
| Grant revenue |
61.51 % |
- |
| Reportable Segment |
11.8 % |
- |
| Alzheimer s Disease Diagnostic Fund |
120 % |
- |
| Eli Lilly Collaboration Agreement |
-25 % |
- |
| UltraDx Limited Company |
-38.89 % |
- |
| Service and Other Revenue North America |
20.93 % |
- |
| Service and Other Revenue EMEA |
73.03 % |
- |
| Service and Other Revenue Asia Pacific |
1.5 % |
- |
| Grant revenue National Institutes of Health |
14.29 % |
- |
| Grant revenue Reportable Segment |
61.51 % |
- |
|
|
